Preclinical Findings

Efficient and precise
lymph node targeting


The Amphiphile platform has been developed and optimized through extensive preclinical testing and validation in the labs at MIT and Elicio. These studies have demonstrated efficient and precise lymph node targeting in mice and non-human primates, where Amphiphiles accumulate broadly in multiple lymph nodes after injection and persist at levels more than 10 times greater than possible through conventional approaches. This improvement in lymph node targeting has resulted in more than a 50-fold enhancement in the delivery of Amphiphile immunogens to immune cells, compared to traditional immunogens. In tests targeting several models of aggressive cancer in mice, Amphiphiles have elicited endogenous cancer-specific immune responses of unprecedented potency, more than 30 times greater than conventional immunogens can achieve. This has resulted in eradication and durable cures of advanced tumors with immune-memory mediating complete protection against future secondary challenge

In combination with engineered anti-tumor immune cells such as CAR-T cells, Amphiphiles have elicited massive expansion (greater than 1,000-fold) of effector immune cells in the lymph nodes following administration to mice. In addition to driving expansion of tumor-targeting immune cells, Amphiphile-driven immune activation in the lymph nodes generates CAR-T cells with greatly enhanced tumor infiltration and anti-tumor functionality, yielding complete cures of aggressive solid tumor models in mice.